X4 Pharmaceuticals, Inc

XFOR

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001501697

SEC filings (opens in a new tab)

Insider trades, last 90 days

0 buys · 3 sells

Sold $356.49K
Open-market purchases (P) and sales (S), counted by Form 4 filing.

View insider trades

13F holders, Q2 2026

89

+5 vs. Q1 2026
Total value $491.87M

View 13F holders

Superinvestors holding XFOR

0

None of the superinvestors held XFOR at the end of Q2 2026.

See all holders

Price chart

Chart by TradingView (opens in a new tab)

Latest insider trades

Open-market purchases and sales by XFOR insiders, newest first.

Insider trades
Filed (ET)	Trade date	Insider	Transaction	Shares	Avg price	Value	Shares after	Holding change	Filing
Aug 13, 20264:13 PM ET	Aug 12, 2026	Volpone JohnPresident	SSaleCommon Stock	−24.58K	$4.4445	−$109.23K	265.31K	−8.5%	SEC
Aug 13, 20264:10 PM ET	Aug 12, 2026	Craig Adam RExecutive Chairman	SSaleCommon Stock	−47.44K	$4.4445	−$210.83K	328.65K	−12.6%	SEC
Jul 1, 20264:23 PM ET	Jun 30, 2026	KIRSKE DAVIDChief Financial Officer	SSaleCommon Stock	−8.54K	$4.2641	−$36.43K	167.75K	−4.8%	SEC
May 13, 2026	May 12, 2026	KIRSKE DAVIDChief Financial Officer	SSaleCommon Stock	−16.96K	$4.29	−$72.76K	176.29K	−8.8%	SEC
Oct 27, 2025	Oct 23, 2025	Craig Adam RExecutive Chairman	PPurchaseCommon Stock	+86.21K	$2.90	+$250K	376.09K	+29.7%	SEC

Top 5 13F holders, Q2 2026

The largest institutional positions in XFOR at the end of Q2 2026.

Institutions holding XFOR in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
MORGAN STANLEY	9,461,279	$44.18M	0.00%	−5,713−0.1%	Reduced
FMR LLC	8,321,657	$38.86M	0.00%	+218,257+2.7%	Added
Bain Capital Life Sciences Investors, LLC	7,967,454	$37.21M	2.21%	00.0%	Unchanged
PERCEPTIVE ADVISORS LLC	7,933,491	$37.05M	0.58%	+1,195,843+17.7%	Added
Kalehua Capital Management LLC	7,445,680	$34.77M	11.09%	00.0%	Unchanged